Immune regulation by rapamycin: Moving beyond T cells

Science Signaling

Volumn 2, Issue 67, 2009, Pages

  Janes, Matthew R ^a   Fruman, David A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; INTERLEUKIN 10; INTERLEUKIN 12; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; RAPAMYCIN; TOLL LIKE RECEPTOR; IMMUNOSUPPRESSIVE AGENT; INTERFERON;

ADAPTIVE IMMUNITY; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; BONE MARROW CELL; CELL FUNCTION; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG EFFICACY; DRUG SENSITIVITY; GRAFT REJECTION; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; INNATE IMMUNITY; LISTERIA MONOCYTOGENES; LISTERIOSIS; LYMPHOCYTE PROLIFERATION; MACROPHAGE; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; REGULATORY T LYMPHOCYTE; SHORT SURVEY; T LYMPHOCYTE; VIRUS INFECTION; ANIMAL; ARTICLE; BIOLOGICAL MODEL; CYTOLOGY; DRUG EFFECT; METABOLISM;

MAMMALIA;

ANIMALS; CYTOKINES; DENDRITIC CELLS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERONS; MACROPHAGES; MODELS, BIOLOGICAL; MYELOID CELLS; SIROLIMUS; T-LYMPHOCYTES; TOLL-LIKE RECEPTORS;

EID: 70349257680     PISSN: 19450877     EISSN: 19379145     Source Type: Journal    
DOI: 10.1126/scisignal.267pe25     Document Type: Short Survey

References (26)

1. C. Vezina, A. Kudelski, S. N. Sehgal, Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J. Antibiot. (Tokyo) 28, 721-726 (1975).
2. R. R. Martel, J. Klicius, S. Galet, Inhibition of the immune response by rapamycin, a new antifungal antibiotic. Can. J. Physiol. Pharmacol. 55, 48-51 (1977). (Pubitemid 8061941)
3. B. K. Law, Rapamycin: An anti-cancer immunosuppressant? Crit. Rev. Oncol. Hematol. 56, 47-60 (2005).
4. S. Wullschleger, R. Loewith, M. N. Hall, TOR signaling in growth and metabolism. Cell 124, 471-484 (2006). (Pubitemid 43199434)
5. W. Cao, S. Manicassamy, H. Tang, S. P. Kasturi, A. Pirani, N. Murthy, B. Pulendran, Toll-like receptor-mediated induction of type I interferon in plasmacytoid dendritic cells requires the rapamycinsensitive PI(3)K-mTOR-p70S6K pathway. Nat. Immunol. 9, 1157-1164 (2008).
6. R. Colina, M. Costa-Mattioli, R. J. Dowling, M. Jaramillo, L. H. Tai, C. J. Breitbach, Y. Martineau, O. Larsson, L. Rong, Y. V. Svitkin, A. P. Makrigiannis, J. C. Bell, N. Sonenberg, Translational control of the innate immune response through IRF-7. Nature 452, 323-328 (2008). (Pubitemid 351430792)
7. M. Ohtani, S. Nagai, S. Kondo, S. Mizuno, K. Nakamura, M. Tanabe, T. Takeuchi, S. Matsuda, S. Koyasu, Mammalian target of rapamycin and glycogen synthase kinase 3 differentially regulate lipopolysaccharide-induced interleukin-12 production in dendritic cells. Blood 112, 635-643 (2008).
8. T. Weichhart, G. Costantino, M. Poglitsch, M. Rosner, M. Zeyda, K. M. Stuhlmeier, T. Kolbe, T M. Stulnig, W. H. Horl, M. Hengstschlager, M. Muller, M. D. Saemann, The TSC-mTOR signaling pathway regulates the innate inflammatory response. Immunity 29, 565-577 (2008).
9. G. B. Barton, R. Medzhitov, Toll-Like Receptor Pathway. Sci. Signal. (Connections Map in the Database of Cell Signaling), http://stke. sciencemag.org/cgi/cm/stkecm;CMP-8643.
10. T. Fukao, M. Tanabe, Y. Terauchi, T. Ota, S. Matsuda, T. Asano, T. Kadowaki, T. Takeuchi, S. Koyasu, PI3K-mediated negative feedback regulation of IL-12 production in DCs. Nat. Immunol. 3, 875-881 (2002).
11. M. Guha, N. Mackman, The phosphatidylinositol 3-kinase-Akt pathway limits lipopolysaccharide activation of signaling pathways and expression of inflammatory mediators in human monocytic cells. J. Biol. Chem. 277, 32124-32132 (2002). (Pubitemid 34969025)
12. M. Martin, R. E. Schifferle, N. Cuesta, S. N. Vogel, J. Katz, S. M. Michalek, Role of the phosphatidylinositol 3 kinase-Akt pathway in the regulation of IL-10 and IL-12 by Porphyromonas gingivalis lipopolysaccharide. J. Immunol. 171, 717-725 (2003). (Pubitemid 36871381)
13. C. Guiducci, C. Ghirelli, M. A. Marloie-Provost, T. Matray, R. L. Coffman, Y. J. Liu, F. J. Barrat, V. Soumelis, PI3K is critical for the nuclear translocation of IRF-7 and type I IFN production by human plasmacytoid predendritic cells in response to TLR activation. J. Exp. Med. 205, 315-322 (2008). (Pubitemid 351281597)
14. T. Weichhart, M. D. Saemann, The PI3K/Akt/mTOR pathway in innate immune cells: Emerging therapeutic applications. Ann. Rheum. Dis. 67 (suppl. 3), iii70-iii74 (2008).
15. +T regulatory cells and promote organ transplant tolerance. J. Immunol. 178, 7018-7031 (2007). (Pubitemid 46847428)
16. S. Haxhinasto, D. Mathis, C. Benoist, The AKTmTOR axis regulates de novo differentiation of CD4+Foxp3+ cells. J. Exp. Med. 205, 565-574 (2008). (Pubitemid 351439304)
17. S. Sauer, L. Bruno, A. Hertweck, D. Finlay, M. Leleu, M. Spivakov, Z. A. Knight, B. S. Cobb, D. Cantrell, E. O'Connor, K. M. Shokat, A. G. Fisher, M. Merkenschlager, T cell receptor signaling controls Foxp3 expression via PI3K, Akt, and mTOR. Proc. Natl. Acad. Sci. U.S.A. 105, 7797-7802 (2008). (Pubitemid 351872718)
18. R. Fischer, H. R. Turnquist, T. Taner, A. W. Thomson, Use of rapamycin in the induction of tolerogenic dendritic cells. Handb. Exp. Pharmacol. 188, 215-232 (2009).
19. E. K. Horibe, J. Sacks, J. Unadkat, G. Raimondi, Z. Wang, R. Ikeguchi, D. Marsteller, L. M. Ferreira, A. W. Thomson, W. P. Lee, M. Feili-Hariri, Rapamycin-conditioned, alloantigen-pulsed dendritic cells promote indefinite survival of vascularized skin allografts in association with T regulatory cell expansion. Transpl. Immunol. 18, 307-318 (2008). (Pubitemid 350297967)
20. W. Reichardt, C. Durr, D. von Elverfeldt, E. Juttner, U. V. Gerlach, M. Yamada, B. Smith, R. S. Negrin, R. Zeiser, Impact of mammalian target of rapamycin inhibition on lymphoid homing and tolerogenic function of nanoparticle-labeled dendritic cells following allogeneic hematopoietic cell transplantation. J. Immunol. 181, 4770-4779 (2008).
21. M. Battaglia, A. Stabilini, E. Draghici, B. Migliavacca, S. Gregori, E. Bonifacio, M. G. Roncarolo, Induction of tolerance in type 1 diabetes via both CD4+CD25+ T regulatory cells and T regulatory type 1 cells. Diabetes 55, 1571-1580 (2006). (Pubitemid 44324109)
22. A. Y. Choo, S. O. Yoon, S. G. Kim, P. P. Roux, J. Blenis, Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation. Proc. Natl. Acad. Sci. U.S.A. 105, 17414-17419 (2008).
23. M. E. Feldman, B. Apsel, A. Uotila, R. Loewith, Z. A. Knight, D. Ruggero, K. M. Shokat, Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol. 7, e38 (2009).
24. C. C. Thoreen, S. A. Kang, J. W. Chang, Q. Liu, J. Zhang, Y. Gao, L. J. Reichling, T. Sim, D. M. Sabatini, N. S. Gray, An ATP-competitive mTOR inhibitor reveals rapamycin-insensitive functions of mTORC1. J. Biol. Chem., E-pub 15 January 2009.
25. C. F. Bentzinger, K. Romanino, D. Cloetta, S. Lin, J. B. Mascarenhas, F. Oliveri, J. Xia, E. Casanova, C. F. Costa, M. Brink, F. Zorzato, M. N. Hall, M. A. Ruegg, Skeletal muscle-specific ablation of raptor, but not of rictor, causes metabolic changes and results in muscle dystrophy. Cell Metab. 8, 411-424 (2008).
26. D. A. Guertin, D. M. Stevens, M. Saitoh, S. Kinkel, K. Crosby, J. H. Sheen, D. J. Mullholland, M. A. Magnuson, H. Wu, D. M. Sabatini, mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice. Cancer Cell 15, 148-159 (2009).